Ask the Expert: Top 3 questions for selecting the right Toxicology partner
In this video, our Discovery Services Head, Dr. Kenneth Barr, shares his views on the key factors your should consider when outsourcing your toxicology program.
Promoting Catalytic C-Selective Sulfonylation of Cyclopropanols against Conventional O-Sulfonylation Using Readily Available Sulfonyl Chlorides
Publication: ACS Publications
First-in-Human Studies Accelerated with Syngene’s CDMO Model
Discover a smarter approach to first-in-human studies with Syngene, integrating discovery, CMC, manufacturing, and governance to de-risk FIH trials.
How Syngene partnered with a bioengineering company to synthesize a complex, triblock copolymer to address biofouling issues
Learn how Syngene synthesized a complex polymer using the RAFT technique and delivered several kilograms of the polymer in just one month.
Leveraging High Throughput Screening services to accelerate drug discovery and development
The many applications of HTS and how it has evolved beyond lead identification and candidate optimization today.
How Syngene supported a biotech in developing a PROTAC molecule for treating cancer
Learn how Syngene successfully developed and manufactured several kilograms of a PROTAC molecule under cGMP conditions within 12 months for treating a certain type of cancer.
Discovery Services
Syngene offers integrated and standalone services across the drug discovery continuum from Target Identification to IND enabling.
Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer
How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.
Viral clearance from conventional to unconventional process steps in Biologics
Learn how viral clearance from unconventional steps can add value to the total viral clearance independently or along with conventional process steps.
How Syngene supported a clinical-stage oncology company in manufacturing the RSM for treating a rare tumour
Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.